Factors associated with ciprofloxacin- and cefotaxime-resistant Escherichia coli in women with acute pyelonephritis in the emergency department

International Journal of Infectious Diseases

Volumn 23, Issue , 2014, Pages 8-13

  Park, Kyung Hwa ^a   Oh, Won Sup ^b   Kim, Eu Suk ^c   Park, Sang Won ^d   Hur, Ji An ^e   Kim, Young Keun ^f   Moon, Chisook ^g   Lee, Jae Hoon ^h   Lee, Chang Seop ⁱ   Kim, Baek Nam ^g  

^a Chonnam National University Medical School   (South Korea)

^b Kangwon National University   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e Yeungnam University College of Medicine   (South Korea)

^f Yonsei University Wonju College of Medicine   (South Korea)

^g Inje University College of Medicine   (South Korea)

^h Wonkwang University   (South Korea)

ⁱ Chonbuk National University Medical School   (South Korea)

Author keywords

Acute pyelonephritis; Cefotaxime; Ciprofloxacin; Resistance; Urinary tract infection; UTI

Indexed keywords

CEFOTAXIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ACUTE PYELONEPHRITIS; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CATHETER INFECTION; CHRONIC KIDNEY DISEASE; COMMUNITY ASSOCIATED ACUTE PYELONEPHRITIS; CONTROLLED STUDY; EMERGENCY HEALTH SERVICE; EMERGENCY WARD; ESCHERICHIA COLI; FEMALE; HEALTHCARE ASSOCIATED ACUTE PYELONEPHRITIS; HEALTHCARE ASSOCIATED INFECTION; HEMATOLOGIC DISEASE; HUMAN; IMMOBILITY; INDWELLING URINARY CATHETER; INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PROSPECTIVE STUDY; URINARY TRACT INFECTION; URINE CULTURE; ACUTE DISEASE; CLINICAL TRIAL; DRUG EFFECTS; EPIDEMIOLOGY; ESCHERICHIA COLI INFECTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; PYELONEPHRITIS; SOUTH KOREA;

ACUTE DISEASE; AGED; ANTI-BACTERIAL AGENTS; CEFOTAXIME; CIPROFLOXACIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EMERGENCY SERVICE, HOSPITAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FLUOROQUINOLONES; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; PYELONEPHRITIS; REPUBLIC OF KOREA;

EID: 84897973763     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2013.12.021     Document Type: Article

References (40)

1. Gupta K., Hooton T.M., Naber K.G., Wullt B., Colgan R., Miller L.G., et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011, 52:e103-e120.
2. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002, 113(Suppl 1A). 5S-13S.
3. Hooton T.M., Clinical practice. Uncomplicated urinary tract infection. N Engl J Med 2012, 366:1028-1037.
4. Clinical guideline for the diagnosis and treatment of urinary tract infections: asymptomatic bacteriuria, uncomplicated and complicated urinary tract infections, bacterial prostatitis. Infect Chemother 2011, 43:1-25. Korean Society of Infectious Diseases, Korean Society for Chemotherapy, Korean Association of Urogenital Tract Infection and Inflammation, Korean Society of Clinical Microbiology.
5. Grabe M., Bjerklund-Johansen T.E., Botto H., Wullt B., Çek M., Naber K.G., et al. Guidelines on urological infections 2011, Available at: http://www.uroweb.org/gls/pdf/15_Urological_Infections.pdf [accessed on December 17, 2013].
6. Zhanel G.G., Hisanaga T.L., Laing N.M., DeCorby M.R., Nichol K.A., Weshnoweski B., et al. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 2006, 27:468-475.
7. Sanchez G.V., Master R.N., Karlowsky J.A., Bordon J.M. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother 2012, 56:2181-2183.
8. Bouchillon S.K., Badal R.E., Hoban D.J., Hawser S.P. Antimicrobial susceptibility of inpatient urinary tract isolates of Gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011. Clin Ther 2013, 35:872-877.
9. Chaniotaki S., Giakouppi P., Tzouvelekis L.S., Panagiotakos D., Kozanitou M., Petrikkos G., et al. Quinolone resistance among Escherichia coli strains from community-acquired urinary tract infections in Greece. Clin Microbiol Infect 2004, 10:75-78.
10. Kahlmeter G., Poulsen H.O. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO.SENS study revisited. Int J Antimicrob Agents 2012, 39:45-51.
11. Lim S.K., Park I.W., Lee W.G., Kim H.K., Choi Y.H. Change of antimicrobial susceptibility among Escherichia coli strains isolated from female patients with community-onset acute pyelonephritis. Yonsei Med J 2012, 53:164-171.
12. Shin J., Kim J., Wie S.H., Cho Y.K., Lim S.K., Shin S.Y., et al. Fluoroquinolone resistance in uncomplicated acute pyelonephritis: epidemiology and clinical impact. Microb Drug Resist 2012, 18:169-175.
13. Canton R., Coque T.M. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol 2006, 9:466-475.
14. Calbo E., Romani V., Xercavins M., Gomez L., Vidal C.G., Quintana S., et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother 2006, 57:780-783.
15. Azap O.K., Arslan H., Serefhanoglu K., Colakoglu S., Erdogan H., Timurkaynak F., et al. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect 2010, 16:147-151.
16. Ha Y.E., Kang C.I., Joo E.J., Park S.Y., Kang S.J., Wi Y.M., et al. Clinical implications of healthcare-associated infection in patients with community-onset acute pyelonephritis. Scand J Infect Dis 2011, 43:587-595.
17. Kim B., Kim J., Wie S.H., Park S.H., Cho Y.K., Lim S.K., et al. Is it acceptable to select antibiotics for the treatment of community-acquired acute cystitis based on the antibiotics susceptibility results for uropathogens from community-acquired acute pyelonephritis in Korea?. Infect Chemother 2012, 44:269-274.
18. Kim B., Kim J., Seo M.R., Wie S.H., Cho Y.K., Lim S.K., et al. Clinical characteristics of community-acquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea. Infection 2013, 41:603-612.
19. Jeon J.H., Kim K., Han W.D., Song S.H., Park K.U., Rhee J.E., et al. Empirical use of ciprofloxacin for acute uncomplicated pyelonephritis caused by Escherichia coli in communities where the prevalence of fluoroquinolone resistance is high. Antimicrob Agents Chemother 2012, 56:3043-3046.
20. Lee S.S., Kim Y., Chung D.R. Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis. J Infect 2011, 62:159-164.
21. Lee S., Song D.Y., Cho S.H., Kwon K.T. Impact of extended-spectrum beta-lactamase on acute pyelonephritis treated with empirical ceftriaxone. Microb Drug Resist 2014, 20(1):39-44.
22. van der Starre W.E., van Nieuwkoop C., Paltansing S., van't Wout J.W., Groeneveld G.H., Becker M.J., et al. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother 2011, 66:650-656.
23. Foxman B. Recurring urinary tract infection: incidence and risk factors. Am J Public Health 1990, 80:331-333.
24. Rubin R.H., Shapiro E.D., Andriole V.T., Davis R.J., Stamm W.E. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992, 15(Suppl 1):S216-S227.
25. Levey A.S., de Jong P.E., Coresh J., Nahas M.E., Astor B.C., Matsushita K., et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011, 80:17-28.
26. Friedman N.D., Kaye K.S., Stout J.E., McGarry S.A., Trivette S.L., Briggs J.P., et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002, 137:791-797.
27. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 20th Informational supplement. CLSI document M100-S20. Wayne, PA: CLSI; 2010.
28. Talan D.A., Krishnadasan A., Abrahamian F.M., Stamm W.E., Moran G.J. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis 2008, 47:1150-1158.
29. Khawcharoenporn T., Vasoo S., Ward E., Singh K. High rates of quinolone resistance among urinary tract infections in the ED. Am J Emerg Med 2012, 30:68-74.
30. Meier S., Weber R., Zbinden R., Ruef C., Hasse B. Extended-spectrum beta-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection 2011, 39:333-340.
31. Aguilar-Duran S., Horcajada J.P., Sorli L., Montero M., Salvado M., Grau S., et al. Community-onset healthcare-related urinary tract infections: comparison with community and hospital-acquired urinary tract infections. J Infect 2012, 64:478-483.
32. Vellinga A., Tansey S., Hanahoe B., Bennett K., Murphy A.W., Cormican M. Trimethoprim and ciprofloxacin resistance and prescribing in urinary tract infection associated with Escherichia coli: a multilevel model. J Antimicrob Chemother 2012, 67:2523-2530.
33. Johnson L., Sabel A., Burman W.J., Everhart R.M., Rome M., MacKenzie T.D., et al. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med 2008, 121:876-884.
34. Colodner R., Kometiani I., Chazan B., Raz R. Risk factors for community-acquired urinary tract infection due to quinolone-resistant. E. coli. Infection 2008, 36:41-45.
35. Arslan H., Azap O.K., Ergonul O., Timurkaynak F. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 2005, 56:914-918.
36. Killgore K.M., March K.L., Guglielmo B.J. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother 2004, 38:1148-1152.
37. Rodriguez-Bano J., Alcala J.C., Cisneros J.M., Grill F., Oliver A., Horcajada J.P., et al. Community infections caused by extended-spectrum beta-lactamase-producing. Escherichia coli. Arch Intern Med 2008, 168:1897-1902.
38. Colodner R., Rock W., Chazan B., Keller N., Guy N., Sakran W., et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004, 23:163-167.
39. Ben-Ami R., Rodriguez-Bano J., Arslan H., Pitout J.D., Quentin C., Calbo E.S., et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009, 49:682-690.
40. Doi Y., Park Y.S., Rivera J.I., Adams-Haduch J.M., Hingwe A., Sordillo E.M., et al. Community-associated extended-spectrum beta-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis 2013, 56:641-648.